

Prof. Sezai VATANSEVER

Personal Information

Office Phone: [+90 212 414 2434](tel:+902124142434) Extension: 34194

Office Phone: [+90 212 414 2434](tel:+902124142434) Extension: 34228

Fax Phone: [+90 212 534 8078](tel:+902125348078)

Email: sezai@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/1244/>

Address: İÜ. Onkoloji Enstitüsü Tıbbi Onkoloji Bilim Dalı Başkanlığı Çapa / Şehremini / Fatih / İstanbul

International Researcher IDs

ORCID: 0000-0002-3108-0686

Publons / Web Of Science ResearcherID: AAY-8457-2020

Yoksis Researcher ID: 102278

Education Information

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Dahili Tıp Bilimleri Bölümü/İç Hastalıkları Anabilim Dalı, Turkey 2008 - 2011

Expertise In Medicine, Istanbul University, Istanbul Medical Faculty, /Dahili Tıp Bilimleri Bölümü/İç Hastalıkları Anabilim Dalı, Turkey 1987 - 1993

Foreign Languages

English, B2 Upper Intermediate

Dissertations

Expertise In Medicine, İyi farklılaşmış tiroid kanserinde klinik seyri ve prognozu etkileyen faktörler (143 hastanın incelenmesi) , Istanbul University, Istanbul Medical Faculty, Dahili Tıp Bilimleri Bölümü/İç Hastalıkları Anabilim Dalı, 1996

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Professor, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 2008 - Continues

Associate Professor, Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , 2004 - 2008

Expert, Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , 1994 - 2004

Academic and Administrative Experience

İstanbul Üniversitesi, Onkoloji Enstitüsü, 2011 - 2013
İstanbul Üniversitesi, Istanbul Medical Faculty, 2007 - 2008

Courses

5. SINIF VAKA DEMONSTRASYONLARI, Undergraduate, 2015 - 2016
ONKOLOJİK ACİLLER, Undergraduate, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2009 - 2010, 2008 - 2009
PRİMERİ BİLİNMEYEN METASTETİK KANSERLERE YAKLAŞIM, Undergraduate, 2013 - 2014, 2011 - 2012, 2010 - 2011, 2009 - 2010, 2008 - 2009
MALİGN EFÜZYONLU HASTAYA YAKLAŞIM, Undergraduate, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2010 - 2011, 2009 - 2010, 2008 - 2009
İLK YARDIM, Associate Degree, 2013 - 2014, 2012 - 2013
ONKOLOJİK DESTEK TEDAVİSİ, Undergraduate, 2013 - 2014, 2011 - 2012, 2010 - 2011, 2009 - 2010, 2008 - 2009
ONKOLOİK DESTEK TEDAVİSİ, Undergraduate, 2012 - 2013
ENDOKRİN ACİLLER, Undergraduate, 2008 - 2009, 2007 - 2008
SIVI ELEKTROLİT DENGESİ, Undergraduate, 2008 - 2009, 2007 - 2008
ASİT BAZ DENGESİ, Undergraduate, 2008 - 2009, 2007 - 2008
SENKOP, Associate Degree, 2008 - 2009, 2007 - 2008
AKUT BÖBREK YETERSİZLİĞİ, Undergraduate, 2008 - 2009, 2007 - 2008
AKUT SOLUNUM YETERSİZLİĞİ, Undergraduate, 2007 - 2008

Advising Theses

VATANSEVER S., Altmış yaş ve üzeri hastalarda demir eksikliği anemisi etyolojisinin araştırılması ve sıklığının saptanması, Expertise In Medicine, M.YÜKSEL(Student), 2008
VATANSEVER S., Türk kadınlarında üst kol çevresi ölçümünün fazla kilo ve obezite ile ilişkisi, Expertise In Medicine, M.AKGÜN(Student), 2005

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Isolated Adrenal Metastases of Castration-Resistant Prostate Cancer**
Topal E., Has Simsek D., Vatansever S., Sanli Y., Kuyumcu S.
CLINICAL NUCLEAR MEDICINE, no.1, 2024 (SCI-Expanded)
- II. **Immune checkpoint inhibitors Assessment of the performance and the agreement of iRECIST, irRC, and irRECIST**
Kızıldağ Yırgın İ., Dogan İ., Engin G., Vatansever S., Erturk S. M.
Journal of Cancer Research and Therapeutics, no.2, pp.1-7, 2023 (SCI-Expanded)
- III. **Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC**
DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., DEMİRKAZIK A., Aydinler A.
MEDICINE, vol.101, no.34, 2022 (SCI-Expanded)
- IV. **Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.**
Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydinler A.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)
- V. **Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer**
Ak N., Vatansever S.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, vol.46, no.6, pp.1787-1791, 2021 (SCI-Expanded)

- VI. **Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center**
Ak N., Toker A., Kara M., Ozkan B., Ulker M., Kaba E., Yegen G., Karaman S., Dagoglu N., Saglam E. K., et al.
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol.29, no.4, pp.487-495, 2021 (SCI-Expanded)
- VII. **Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.**
Aydiner A., Dogan I., Khanmammadov N., Saip P., Vatansever S.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)
- VIII. **Outcomes of ROS1 positive metastatic lung cancer patients treated with crizotinib**
Dogan I., Khanmammadov N., Paksoy N., Ferhatoglu F., Aydin E., Vatansever S., Saip P., Aydiner A.
JOURNAL OF THORACIC ONCOLOGY, vol.16, no.4, 2021 (SCI-Expanded)
- IX. **Predictors of treatment response in ALK-positive metastatic non-small cell lung cancer**
Dogan I., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., Demirkazik A., Aydiner A.
JOURNAL OF THORACIC ONCOLOGY, vol.16, no.4, 2021 (SCI-Expanded)
- X. **Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.**
Dogan I., Iribas A., Paksoy N., Ekenel M., Vatansever S., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.6, 2021 (SCI-Expanded)
- XI. **"Door to Treatment" Outcomes of Cancer Patients during the COVID-19 Pandemic**
Ak N., Vatansever S.
CHEMOTHERAPY, vol.65, no.5-6, pp.141-146, 2021 (SCI-Expanded)
- XII. **The expression level of fibulin-2 in the circulating RNA (ctRNA) of epithelial tumor cells of peripheral blood and tumor tissue of patients with metastatic lung cancer**
Avsar M., Tambas M., Yalniz Z., Akdeniz D., Tuncer S., Kilic S., Sukruoglu E., Ciftci R., Dagoglu N., Vatansever S., et al.
MOLECULAR BIOLOGY REPORTS, no.4, pp.4001-4008, 2019 (SCI-Expanded)
- XIII. **Vemurafenib-induced toxic epidermal necrolysis: Is it an emerging side-effect of the drug?**
Kilic S., Ozkaya E., Baykal C., Vatansever S.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, vol.31, 2017 (SCI-Expanded)
- XIV. **Is it solitary plasmacytoma or nonsecretory myeloma? A must-be-solved dilemma?**
Erturk K., Tastekin D., Gundogdu G., Tas F., Vatansever S.
BIOMEDICINE & PHARMACOTHERAPY, vol.77, pp.27-29, 2016 (SCI-Expanded)
- XV. **Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer**
Erturk K., Tastekin D., Serilmez M., Bilgin E., Bozbey H. U., Vatansever S.
TUMOR BIOLOGY, vol.37, no.1, pp.405-412, 2016 (SCI-Expanded)
- XVI. **The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer**
Karabulut S., Tas F., Tastekin D., KARABULUT M., Yasasever C., Ciftci R., Guveli M., Fayda M., Vatansever S., Serilmez M., et al.
TUMOR BIOLOGY, vol.35, no.9, pp.8849-8860, 2014 (SCI-Expanded)
- XVII. **Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?**
Karabulut S., Aksit E., Tas F., Ciftci R., Aydiner A., Yildiz I., Keskin S., Eralp Y., Yasasever C. T., Vatansever S., et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, no.5, pp.4323-9, 2014 (SCI-Expanded)
- XVIII. **Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma**
Karabulut S., Duranyildiz D., Tas F., Gezer U., Akyuz F., Serilmez M., Ozgur E., Yasasever C. T., Vatansever S., Aykan N. F.
TUMOR BIOLOGY, vol.35, no.3, pp.2729-2739, 2014 (SCI-Expanded)
- XIX. **Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma**

Karabulut S., Tas F., Akyuz F., Ormeci A., Serilmez M., Soydinc H. O., Vatansever S., Yasasever V.

TUMOR BIOLOGY, vol.35, no.3, pp.2327-2333, 2014 (SCI-Expanded)

- XX. **High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer**
Ciftci R., Tas F., Yasasever C., Aksit E., Karabulut S., Sen F., Keskin S., Kilic L., Yildiz I., Bozbey H. U., et al.
Tumor Biology, vol.35, no.7, pp.6941-6948, 2014 (SCI-Expanded)
- XXI. **The Role of Surgical Methods in the Treatment of Anorectal Malignant Melanoma (AMM)**
Keskin S., Tas F., Karabulut S., Yildiz I., Kilic L., Ciftci R., Vatansever S.
ACTA CHIRURGICA BELGICA, vol.113, no.6, pp.429-433, 2013 (SCI-Expanded)
- XXII. **Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.**
Keskin S., Tas F., Ekenel M., Kilic L., Sen F., Yildiz I., Karabulut S., Ciftci R., Vatansever S.
Tumori, vol.99, no.4, pp.463-8, 2013 (SCI-Expanded)
- XXIII. **Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome.**
Keskin S., Tas F., Vatansever S.
Urologia internationalis, vol.90, no.4, pp.435-8, 2013 (SCI-Expanded)
- XXIV. **A CASE OF PARANEOPLASTIC LIMBIC ENCEPHALITIS DUE TO GASTRIC CARCINOMA PRESENTING WITH PANHYPOPITUITARISM**
Kayacan S., Vatansever S., Yilmaz A., Kayacan D., Karadag A., Akkaya V., Erk O., Guler K.
NOBEL MEDICUS, vol.9, no.1, pp.121-123, 2013 (SCI-Expanded)
- XXV. **Factors Associated with Late Toxicity in Nasopharyngeal Carcinoma Patients Treated with Radio-Chemotherapy**
Meral R., Camlica H., Vatansever S.
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, vol.30, no.1, pp.37-47, 2010 (SCI-Expanded)
- XXVI. **High Sensitivity C- Reactive Protein In Spontaneous Bacterial Peritonitis with Nonneutrocytic Ascites**
Guler K., Vatansever S., Kayacan S. M., Salmayenli N., Akkaya V., Erk O., Palanduz A.
HEPATO-GASTROENTEROLOGY, vol.56, no.90, pp.452-455, 2009 (SCI-Expanded)
- XXVII. **Alveolar echinococcosis localized in the liver, lung and brain**
Kayacan S. M., Vatansever S., Temiz S., Uslu B., Kayacan D., Akkaya V., Erk O., Saka B., Karadag A., Turkmen K., et al.
CHINESE MEDICAL JOURNAL, no.1, pp.90-92, 2008 (SCI-Expanded)
- XXVIII. **A case of inflammatory pseudotumor in the spleen**
CELEBI A., Kayacan S. M., Keskin S., TEMELOGLU E., KOC D., ERCAN V., ESIN D., EKIZOGLU I., Vatansever S., GULLUOGLU M., et al.
SOUTHERN MEDICAL JOURNAL, vol.99, no.7, pp.774-776, 2006 (SCI-Expanded)
- XXIX. **The effect of air pollution and meteorological parameters on chronic obstructive pulmonary disease at an Istanbul hospital**
Hapcioglu B., Issever H., Kocyigit E., Disci R., Vatansever S., OZDILLI K.
INDOOR AND BUILT ENVIRONMENT, vol.15, no.2, pp.147-153, 2006 (SCI-Expanded)
- XXX. **Effect of apoptosis and response of extracellular matrix proteins after chemotherapy application on human breast cancer cell spheroids**
OKTEM G., Vatansever S., AYL A S., UYSAL A., AKTAS S., KARABULUT B., BILIR A.
ONCOLOGY REPORTS, vol.15, no.2, pp.335-340, 2006 (SCI-Expanded)
- XXXI. **The effect of air pollution and meteorological parameters in Istanbul on hospital admissions for acute coronary syndrome**
Issever H., Disci R., HAPCIOGLU B., Vatansever S., Karan M. A., Akkaya V. A., Erk O.
INDOOR AND BUILT ENVIRONMENT, vol.14, no.2, pp.157-164, 2005 (SCI-Expanded)
- XXXII. **Pre-ischemic administration of nitric oxide synthase inhibitors reduced germ cell apoptosis after spermatic vessel ligation in the rat testis**
Taneli F., VATANSEVER S., Ulman C., Giray G., Genc A., Taneli C.
UROLOGIA INTERNATIONALIS, vol.75, no.1, pp.70-74, 2005 (SCI-Expanded)
- XXXIII. **Sister chromatid exchange and mitotic index in patients with cirrhosis related to hepatitis B and C**

viruses and in chronic carriers

Ucur A., Palanduz S., Cefle K., Ozturk Ş., Tutkan G., Vatansever S., Erden S., Karan M., Erten N., Guler K., et al.
HEPATO-GASTROENTEROLOGY, vol.50, no.54, pp.2137-2140, 2003 (SCI-Expanded)

XXXIV. Rheological properties of blood in patients with chronic liver disease

Tamer S., Cefle K., Palanduz S., Vatansever S.

CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, vol.26, no.1, pp.9-14, 2002 (SCI-Expanded)

XXXV. Questioning the psycho-socio-cultural factors that contribute to the cases of suicide attempts: an investigation

Tüzün B., Polat O., Vatansever S., Elmas I.

FORENSIC SCIENCE INTERNATIONAL, vol.113, pp.297-301, 2000 (SCI-Expanded)

XXXVI. A case of Noonan syndrome with pulmonary and abdominal lymphangiectasia

Ozturk Ş., Cefle K., Palanduz S., Erten N., Karan M., Tascioglu C., Umman S., Falay O., Vatansever S., Guler K., et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.54, no.4, pp.274-276, 2000 (SCI-Expanded)

XXXVII. Rheological properties of blood in patients with ischaemic heart disease

Palanduz S., Tamer S., Vatansever S., Karan M., Cefle K., Ozturk Ş., Guler K., Kudat H., Kayserilioglu A.

MEDICAL SCIENCE RESEARCH, vol.27, no.5, pp.327-329, 1999 (SCI-Expanded)

XXXVIII. Total antioxidant status, lipid parameters, lipid peroxidation and glutathione levels in patients with acute myocardial infarction

Guler K., Palanduz S., Ademoglu E., Salmayenli N., Gokkusu C., Vatansever S.

MEDICAL SCIENCE RESEARCH, vol.26, no.2, pp.105-106, 1998 (SCI-Expanded)

Articles Published in Other Journals

I. Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients

Dogan I., Yildiz A., Ahmed M. A., Vatansever S.

Indian Journal of Surgical Oncology, 2024 (ESCI)

II. Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study

FERHATOĞLU F., ÇAĞATAY T., OKUMUŞ G., AYDINER A., PAKSOY N., VATANSEVER S., AYDIN E., SAİP P.

Eurasian Journal of Medical Investigation, vol.7, no.2, pp.101-106, 2023 (Peer-Reviewed Journal)

III. Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors

DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.

Eurasian Journal of Pulmonology, vol.25, no.1, pp.27-32, 2023 (Peer-Reviewed Journal)

IV. Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine

DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.

European Journal of Breast Health, vol.19, no.2, pp.128-133, 2023 (Scopus)

V. The Significance of Preoperative Computed Tomography Features in the Prediction of Overall Survival in Gastric Cancer: A Retrospective Analysis

Kızıldağ Yırgın İ., Dogan İ., Vatansever S., Erturk S. M.

MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL, no.1, pp.1-5, 2023 (Peer-Reviewed Journal)

VI. Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study

Yekeduz E., Dogan I., Kaya D. M., Ozgur I., UTKAN G., Vatansever S., DEMİRCİ S., AKBULUT H., ÜRÜN Y.

JOURNAL OF GASTROINTESTINAL CANCER, vol.53, no.4, pp.870-879, 2022 (ESCI)

VII. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib

DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.

CLINICAL CANCER INVESTIGATION JOURNAL, no.4, pp.5-9, 2022 (ESCI)

- VIII. **Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience**
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.
CLINICAL CANCER INVESTIGATION JOURNAL, no.3, pp.25-29, 2022 (ESCI)
- IX. **Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib**
Dogan I., Khanmammadov N., Paksoy N., Ferhatoglu F., Aydın E., Vatansever S., Aydin A.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.37, pp.413-418, 2022 (ESCI)
- X. **Metastases to the Stomach: Clinicopathologic Features of Metastases Mimicking Gastric Primaries**
ALTAY A. Y., BÜYÜK M., ÖZGÜR İ., GÖK A. F. K., ÇAVUŞ B., AYDIN E., VATANSEVER S., GÜLLÜOĞLU M.
TURKISH JOURNAL OF PATHOLOGY, vol.37, no.3, pp.203-211, 2021 (ESCI)
- XI. **Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma**
Naziye A. K., Paksoy N., Ferhatoglu F., Aydın E., Dogan I., Bektas E., Karaca M., Oguz Soydu H., Minareci Y., Sozen H., et al.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.36, pp.438-445, 2021 (ESCI)
- XII. **Nectin-2 and Nectin-4 Adhesion Molecules in Patients with Breast Cancer**
Ak N., Serilmez M., Ucuncu M. Z., Bademler S., Vatansever S.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.36, no.2, pp.165-170, 2021 (ESCI)
- XIII. **Rare pancreas tumor mimicking adenocarcinoma: Extramedullary plasmacytoma**
AKYÜZ F., Sahin D., Akyuz U., VATANSEVER S.
WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY, vol.6, no.3, pp.99-100, 2014 (ESCI)
- XIV. **A CASE OF LEPTOSPIROSIS PRESENTING WITH NEPHROTIC SYNDROME, ACUTE RENAL FAILURE AND THROMBOCYTOPENIA**
Kayacan S. M., VATANSEVER S., Karada A., ERK O., Kilic L., Bal H., Akkaya V., GÜLER K.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.72, no.1, pp.25-28, 2009 (ESCI)
- XV. **A CASE OF COPPER SULFATE INTOXICATION THAT IS PRESENTED WITH PROLONGED HEMOLYSIS AND ACUTE RENAL FAILURE**
Kayacan S. M., VATANSEVER S., Akkaya V., ERK O., Tukek T., KILIÇASLAN I., YILDIZ A., GÜLER K.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.70, no.2, pp.47-50, 2007 (ESCI)
- XVI. **CANDIDA KEFIR PNEUMONIA**
Kocabay G., Aydın S., Tiryak B., VATANSEVER S., ERK O., Akkaya V., GÜLER K.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.68, no.1, pp.26-28, 2005 (ESCI)
- XVII. **A CASE OF METHEMOGLOBINEMIA INDUCED BY THE ADMINISTRATION OF PRILOCAINE PRIOR TO AN EPILATION PROCEDURE**
Turkmen E., Kocabay G., YAVUZ A. F., ÖZTÜRK S., VATANSEVER S., Akkaya V., ERK O., GÜLER K.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.68, no.1, pp.19-21, 2005 (ESCI)
- XVIII. **UNILATERAL RENALARTERY THROMBOEMBOLISM IN A PATIENT WITH ATRIAL FIBRILLATION**
ELİTOK A., Yilmaz C., Karakaya D., Barman A., VATANSEVER S., Akkaya V., ERK O., GÜLER K.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.68, no.2, pp.53-55, 2005 (ESCI)
- XIX. **Evde Hazırlanmış Konserve Bezelye Yenilmesi Sonucu Tip A Nörotoksinine Bağlı Botulizm Vakası**
TÜRKMEN E., KOCABAY G., SOYLUK SELÇUKBİRİCİK Ö., VATANSEVER S., GÜLER K., AKKAYA V. A., DİLMENER M.
İstanbul Tıp Fakültesi Mecmuası, 2003 (Peer-Reviewed Journal)

Books & Book Chapters

- I. **The role of surgical methods in the treatment of anorectal malignant melanoma (AMM).**
VATANSEVER S., TAŞ F., Yıldız I., Kilic L., Ciftci R., Karabulut S., KESKİN S.
Acta Chirurgica Belgica, İstanbul, 2013
- II. **KOMA**
VATANSEVER S., TAŞCIOĞLU C., KARAN M. A., BEŞİŞİK S. F., KRESPI Y.
in: ACİL DAHİLİYE, CALANGU S, GULER K, Editor, Nobel Tıp Kitabevleri Ltd. Şti., İstanbul, pp.677-694, 2009
- III. **ZEHİRLENMELER**
VATANSEVER S., GÜLER K.
in: ACİL DAHİLİYE, CALANGU S, GULER K, , Editor, Nobel Tıp Kitabevleri Ltd. Şti., İstanbul, pp.657-675, 2009
- IV. **Preoperatif dönemde tıbbi konsültasyonun önemi ve beklentiler.**
TUĞRUL K. M., VATANSEVER S.
in: Perioperatif iç hastalıkları konsültasyonu, Mehmet Akif Karan, Editor, Nobel Tıp Kitabevi, İstanbul, pp.9-18, 2003

Refereed Congress / Symposium Publications in Proceedings

- I. **Non-operative management in locally advanced distal rectal cancer patients with clinical complete response after consolidation chemoradiotherapy: A single center experience**
Kulle C. B., Özgür İ., Bayraktar A., Güden İ., Karaman Ş., Vatansever S., Acunaş B., Bulut M. T., Keskin M.
ESCP 17th Scientific & Annual Meeting, Dublin, Ireland, 21 - 23 September 2022, vol.24, no.1, pp.1-315
- II. **Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis**
Dogan I., Kızıldağ Yırgın İ., Özkurt S., İbiş K., Vatansever S., Saip P. M., Aydinler A.
2022 ASCO Annual Meeting , Illinois, United States Of America, 3 - 07 June 2022, pp.14002
- III. **Evaluation of the relationship between clinicopathological features at diagnosis and acquisition of T790M resistance mutation in patients with EGFR-mutant metastatic lung cancer**
Dogan I., Khanmamadov N., Paksoy N., Vatansever S., Saip P., Aydinler A.
Molecular Analysis for Precision Oncology Virtual Congress, ELECTR NETWORK, 7 - 09 October 2021, vol.32
- IV. **Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation**
Dogan I., Gurbuz M., Paksoy N., Khanmamadov N., Vatansever S., Saip P., Demirkazık A., Aydinler A.
Molecular Analysis for Precision Oncology Virtual Congress, ELECTR NETWORK, 7 - 09 October 2021, vol.32
- V. **The Significance Of Preoperative Computed Tomography Features In The Prediction Of Overall Survival In Gastric Cancer: A Retrospective Analysis.**
Kızıldağ Yırgın İ., Ertürk S. M., Dogan I., Vatansever S.
ECR2021, Vienna, Austria, 3 - 07 March 2021, pp.10-11
- VI. **iRECIST, irRC and irRECIST: A Pairwise Agreement and Performance Evaluation Study**
Kızıldağ Yırgın İ., Doğan İ., Vatansever S., Ertürk Ş. M.
RSNA2020, Illinois, United States Of America, 24 - 29 November 2020, pp.988
- VII. **BAĞIŞIKLIK KONTROL NOKTASI İNHİBİTÖRLERİ: İRECIST, İRRC VE İRRECIST'İN PERFORMANSLARININ VE UYUMLARININ DEĞERLENDİRİLMESİ IMMUNE CHECKPOINT İNHİBİTORS: ASSESSMENT OF THE PERFORMANCE AND THE AGREEMENT OF İRECIST, İRRC AND İRRECIST**
Kızıldağ Yırgın İ., Doğan İ., Vatansever S., Ertürk Ş. M.
41.Ulusal Radyoloji Kongresi, Antalya, Turkey, 24 October - 01 November 2020, pp.205-206
- VIII. **Trastuzumab-based treatment of HER2-positive metastatic gastric cancer**
Dogan I., Karabulut S., Tastekin D., Paksoy N., Sakar B., Vatansever S.
ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 July 2020, vol.31
- IX. **Mide Kanserinde Serum Interleukin-29, Interleukin-32 ve Tumor Necrosis Factor Alpha'nın Klinik Önemi**
ERTÜRK K., TAŞTEKİN D., SERİLMEZ M., BİLGİN DOĞRU E., H. U., VATANSEVER S.
3. Ulusal İmmüno-Onkoloji ve Hedefe Yönelik Kanser Tedavileri Kongresi, Antalya, Turkey, 11 - 15 May 2016, pp.1

- X. **Clinical significance of serum claudin-7 levels in patients with colorectal cancer.**
Aydoğan F., Karabulut M., Alis H., Karabulut S., Celebi K., Bozbey H. U., Erturk K., Vatansever S., Aykan N. F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XI. **Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?**
Basaran M., KARABULUT S., KARABULUT M., GUNALDI M., ALIS H., Erturk K., Vatansever S., Sakar B., Aykan N. F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XII. **Factors affecting progression free survival in non-HIV related classical Kaposi sarcoma.**
Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U., Karanlik H., Kurul S., Vatansever S., Saip P., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIII. **Prognostic roles of serum NEDD9 levels in patients with gastric cancer.**
Karabulut S., Karabulut M., Alis H., Bozbey H. U., Sakar B., Vatansever S., Aykan N. F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIV. **Clinical significance of serum vascular cell adhesion molecule-1 (VCAM-1) in colorectal cancer**
Ciftci R., Aykan N. F., Aksit E., YASASEVER C. T., Vatansever S., Yasasever V.
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 15 - 17 January 2015, vol.33
- XV. **Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.**
CIFTCI R., Tas F., AKSIT E., Vatansever S., KARABULUT S., Sen F., YILDIZ I., Keskin S., BOZBEY H. U., Kilic L., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XVI. **Clinical significance of serum transforming growth factor beta 1 (TGFB1) level in breast cancer.**
CIFTCI R., Tas F., Kilic L., Vatansever S., KARABULUT S.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XVII. **AKCİĞER KANSERLİ HASTALARDA FİBULİN-2 GENİNİN ARAŞTIRILMASI**
avşar m., AKDENİZ ÖDEMİŞ D., TUNÇER Ş. B., çiftçi r., DAĞOĞLU R. N., ahmedova a., TAMBAŞ M., POYRAZ K., VATANSEVER S., YAZICI H.
6. ulusal akciğer kanser kongresi, Antalya, Turkey, 8 - 11 May 2014
- XVIII. **Meme Kanserli Hastalarda Serum Par-1 (Protease Activated Receptor-1) Düzeylerinin Klinik Açıdan Önemi**
Ciftci R., Karabulut S., Aksit E., TAŞ F., TILGEN YASASEVER C., VATANSEVER S., DURANYILDIZ H. D., Kilic L.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.500
- XIX. **Epitelyal Over Kanserli Hastalarda Yüksek Serum Epidermal Büyüme Faktör Reseptörü (EGFR) Düzeyleri Kötü Progresyonsuz Sağkalımla İlişkilidir**
Karabulut S., Ciftci R., Tastekin D., TILGEN YASASEVER C., VATANSEVER S., Duranyildiz D., TAŞ F., Aydiner A., SAİP P. M.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.428
- XX. **Serum Transforme Edici Büyüme Faktörü-Beta1 (TGF-B1) Seviyelerinin Epitelyal Over Kanserli Hastalarda Klinik Önemi**
Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., TAŞ F., TILGEN YASASEVER C., DURANYILDIZ H. D., Aydiner A., SAİP P. M.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421
- XXI. **Meme Kanserli Hstalarda Serum MIF (Macrophage Migration Inhibitory Factor) Düzeylerinin Klinik Açıdan Önemi**

Ciftci R., Karabulut S., TİLGİN YASASEVER C., Aksit E., Yildiz I., BİLGİN DOĞRU E., Tas F., Vatansever S., Keskin S., VATANSEVER S., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.501

XXII. Serum Hücresel Adhezyon Molekülleri (VCAM-1, EPCAM) Seviyelerinin Meme Kanseri Hastalarında Tanısal, Prediktif ve Prognostik Rolü

Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., Aydinler A., TİLGİN YASASEVER C., Duranyildiz D., SAİP P. M.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.493

XXIII. Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma

Karabulut S., Aykan N. F., Yildiz I., Kilic L., Sen F., Vatansever S.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 16 - 18 January 2014, vol.32

XXIV. Clinical significance of coagulation assays in metastatic pancreas adenocarcinoma

VATANSEVER S., Tas F., Yildiz I., Kilic L., Ciftci R., Karabulut S., Keskin S.

7th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49, pp.600-601

XXV. Prognostic factors in metastatic pancreatic cancer: Older patients have poorer prognosis

Ciftci R., Karabulut S., Aydogan F., Kilic L., Keskin S., Yildiz I., Vatansever S., Tas F.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49

XXVI. İstanbul Üniversitesi Biyomedikal ve Klinik Mühendisliği Birimi'nde ISO 9001:2008 Kalite Yönetim Sistemi Uygulaması

SEZDİ M., ODABAŞIOĞLU N., AKAN A., SELVİ Y., VATANSEVER S.

Tıp Teknolojileri Ulusal Kongresi, Antalya, Turkey, 14 - 16 October 2010, pp.69-71

XXVII. Tıbbi Cihaz Kazalarında Olay Bildirimi

AKAN A., SELVİ Y., VATANSEVER S., Sezdi M.

8. Uusal Sağlık Kuruluşları Yönetimi Kongresi, SYD-2010, Muğla, Turkey, 13 - 16 May 2010, pp.429-432

XXVIII. Tıbbi Cihaz Satın Alma Süreçlerinin Yönetimi

Sezdi M., AKAN A., SELVİ Y., VATANSEVER S.

8. Uusal Sağlık Kuruluşları Yönetimi Kongresi, SYD-2010, Muğla, Turkey, 13 - 16 May 2010, pp.38-44

XXIX. Medikal Kalibrasyonun Hasta Güvenliği Açısından Önemi, Kontrolü ve Akreditasyon

SEZDİ M., ÖZSARI S. H., SELVİ Y., VATANSEVER S., AKAN A.

”, II. Uluslararası Sağlıkta Performans ve Kalite Kongresi, Antalya, Turkey, 28 April - 01 May 2010, pp.73-77

XXX. A case of acute renal failure due to copper sulfate intoxication

Kayacan S. M., Vatansever S., Akkaya V., Erk O., Guler K.

43rd ERA-EDTA Congress, Glasgow, United Kingdom, 15 - 18 July 2006, vol.21, pp.110

Metrics

Publication: 91

Citation (WoS): 194

Citation (Scopus): 200

H-Index (WoS): 9

H-Index (Scopus): 9